Krystal Biotech, Inc. — Director's Dealing 2021

Mar 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2021-02-26

Reporting Person: Krishnan Krish S (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-26	Common Stock	A	40800	—	Acquired	1927262	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-26	Stock Option (Right to Buy)	$78.89	A	61200	Acquired	2025-02-26	Common Stock (61200)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	112162	Indirect
Common Stock	1864464	Indirect

Footnotes

F1: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022.

F2: Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.

F3: Directly beneficially owned by Suma S. Krishnan, the spouse of the reporting person.

F4: The option vests in four equal annual installments beginning on February 26, 2022.